News on Blepharospasm from BioPortfolio.com http://www.BioPortfolio.com Consolidated Blepharospasm news from BioPortfolio.com Tue, 09 Feb 2010 23:51:25 GMT en MERZ Pharma Canada Inc. is Proud to Announce That Xeomin(R) has Received Exception Drug Status From the Conseil du medichttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012854&HITNO=0&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012854&THISHREF=http://c.moreover.com/click/here.pl%3fz2523541491%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012854&HITNO=0&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012854&THISHREF=http://c.moreover.com/click/here.pl%3fz2523541491%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsBlaze: MERZ Pharma Canada Inc. is Proud to Announce That Xeomin(R) has Received Exception Drug Status From the Conseil du medicament duhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014342&HITNO=1&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014342&THISHREF=http://c.moreover.com/click/here.pl%3fz2523971503%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014342&HITNO=1&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014342&THISHREF=http://c.moreover.com/click/here.pl%3fz2523971503%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEuroInvestor.co.uk: MERZ Pharma Canada Inc. is Proud to Announce That Xeomin(R) has Received Exception Drug Status From the Conseil du medicament du Quebec(i)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013055&HITNO=2&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013055&THISHREF=http://c.moreover.com/click/here.pl%3fz2523596063%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013055&HITNO=2&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013055&THISHREF=http://c.moreover.com/click/here.pl%3fz2523596063%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: MERZ Pharma Canada Inc. is Proud to Announce That Xeomin(R) has Received Exception Drug Status From the Conseil du medicament du Quebec(i)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013048&HITNO=3&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013048&THISHREF=http://c.moreover.com/click/here.pl%3fz2523594178%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013048&HITNO=3&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013048&THISHREF=http://c.moreover.com/click/here.pl%3fz2523594178%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: MERZ Pharma Canada Inc. is Proud to Announce That Xeomin(R) has Received Exception Drug Status From the Conseihttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013032&HITNO=4&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013032&THISHREF=http://c.moreover.com/click/here.pl%3fz2523589798%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013032&HITNO=4&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013032&THISHREF=http://c.moreover.com/click/here.pl%3fz2523589798%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMarketwire via Yahoo!: MERZ Pharma Canada Inc. is Proud to Announce That Xeomin(R) has Received Exception Drug Status Fromhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013029&HITNO=5&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013029&THISHREF=http://c.moreover.com/click/here.pl%3fz2523588719%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013029&HITNO=5&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013029&THISHREF=http://c.moreover.com/click/here.pl%3fz2523588719%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInterest!ALERT: Prospective, Randomized, Double-Blind Study, Comparing Botulinum Toxins Type A Botox and Prosigne for Blepharospasm and Hemifacial Spasm Treatmenthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003855&HITNO=6&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003855&THISHREF=http://c.moreover.com/click/here.pl%3fz2519706567%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003855&HITNO=6&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003855&THISHREF=http://c.moreover.com/click/here.pl%3fz2519706567%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Photophobia in essential blepharospasm - A positron emission tomographic studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999113&HITNO=7&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999113&THISHREF=http://c.moreover.com/click/here.pl%3fz2517325388%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999113&HITNO=7&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999113&THISHREF=http://c.moreover.com/click/here.pl%3fz2517325388%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMovement Disorders: Research points to expanding role of botulinum toxin in several urologic indicationshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988408&HITNO=8&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988408&THISHREF=http://c.moreover.com/click/here.pl%3fz2511006390%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988408&HITNO=8&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988408&THISHREF=http://c.moreover.com/click/here.pl%3fz2511006390%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comUrology Times: Neurotoxins: Scientists at Merz Pharmaceuticals GmbH release new data on neurotoxinshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3967601&HITNO=9&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3967601&THISHREF=http://c.moreover.com/click/here.pl%3fz2499821151%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3967601&HITNO=9&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3967601&THISHREF=http://c.moreover.com/click/here.pl%3fz2499821151%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Extension Application for Xeomin for the New Indication Spasticity was Approved in Various European Countrieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3657337&HITNO=10&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3657337&THISHREF=http://c.moreover.com/click/here.pl%3fz2343132771%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3657337&HITNO=10&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3657337&THISHREF=http://c.moreover.com/click/here.pl%3fz2343132771%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Merz Pharmaceuticals Announces Approval of Post-stroke Upper Limb Spasticity Indication for Xeomin(R) in the Ehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3655134&HITNO=11&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3655134&THISHREF=http://c.moreover.com/click/here.pl%3fz2342351196%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3655134&HITNO=11&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Blepharospasm&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3655134&THISHREF=http://c.moreover.com/click/here.pl%3fz2342351196%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire via Yahoo!: